Verbaan, D.

disease patient parkinson study mutation fatigue scale activity analysis dyskinesia group score exercise disorder movement onset signi 1761r severity ataxia family neurol signi ficantly disease duration duration park 2 gene result rating baseline fatigue severity scale table psp-p disord rearrangement participant control carrier lrrk 2 mutations parkinsonism follow-up assessment parkin genotype neurology deletion polymorphism supranuclear development region population haplotype hypometabolism 158met activity scale syndrome range supranuclear palsy brain friedreich interest /financial disclosures effect p.s 1761r mutation lopd patients fi nancial disclosures novel lrrk 2 gene disease severity ficantly people pd patients richardson frequency domain thalamic dopamine park 2 parkinson disease method supranuclear palsy-parkinsonism society